MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: Clinical trials to clinical practice

Journal of Hepatology

Volumn 65, Issue 5, 2016, Pages 1006-1016

  Dulai, Parambir S ^a   Sirlin, Claude B ^a   Loomba, Rohit ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Magnetic resonance elastography; Magnetic resonance imaging; Non alcoholic fatty liver disease; Non alcoholic steatohepatitis

Indexed keywords

BIOLOGICAL MARKER;

CLINICAL PRACTICE; COMPARATIVE EFFECTIVENESS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FATTY LIVER; HUMAN; LIVER FIBROSIS; MAGNETIC RESONANCE ELASTOGRAPHY; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTON DENSITY FAT FRACTION; RADIOLOGICAL PARAMETERS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELIABILITY; REPRODUCIBILITY; REVIEW; VALIDITY; BIOPSY; LIVER CIRRHOSIS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY;

BIOPSY; HUMANS; LIVER CIRRHOSIS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 84995360076     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.06.005     Document Type: Review

References (122)

1. [1] Loomba, R., Sanyal, A.J., The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol 10 (2013), 686–690.
2. [2] Vernon, G., Baranova, A., Younossi, Z.M., Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 34 (2011), 274–285.
3. [3] Rinella, M.E., Nonalcoholic fatty liver disease: a systematic review. JAMA 313 (2015), 2263–2273.
4. [4] Chalasani, N., Younossi, Z., Lavine, J.E., et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 142 (2012), 1592–1609.
5. [5] Spengler, E.K., Loomba, R., Recommendations for diagnosis, referral for liver biopsy, and treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Mayo Clin Proc 90 (2015), 1233–1246.
6. [6] Matteoni, C.A., Younossi, Z.M., Gramlich, T., et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116 (1999), 1413–1419.
7. [7] Singh, S., Allen, A.M., Wang, Z., et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 13 (2015), 643–654, e1–e9 [Quiz e39–e40].
8. [8] Wong, V.W., Wong, G.L., Choi, P.C., et al. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut 59 (2010), 969–974.
9. [9] Bhala, N., Angulo, P., van der Poorten, D., et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology 54 (2011), 1208–1216.
10. [10] Adams, L.A., Lymp, J.F., St Sauver, J., et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 129 (2005), 113–121.
11. [11] Arulanandan, A., Ang, B., Bettencourt, R., et al. Association between quantity of liver fat and cardiovascular risk in patients with nonalcoholic fatty liver disease independent of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 13 (2015), 1513–1520, e1.
12. [12] http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugDevelopmentToolsQualificationProgram/ucm459144.htm.
13. [13] Rockey, D.C., Caldwell, S.H., Goodman, Z.D., et al. Liver biopsy. Hepatology 49 (2009), 1017–1044.
14. [14] Asrani, S.K., Incorporation of noninvasive measures of liver fibrosis into clinical practice: diagnosis and prognosis. Clin Gastroenterol Hepatol 13 (2015), 2190–2204.
15. [15] Bravo, A.A., Sheth, S.G., Chopra, S., Liver biopsy. N Engl J Med 344 (2001), 495–500.
16. [16] Regev, A., Berho, M., Jeffers, L.J., et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 97 (2002), 2614–2618.
17. [17] Bonekamp, S., Tang, A., Mashhood, A., et al. Spatial distribution of MRI-Determined hepatic proton density fat fraction in adults with nonalcoholic fatty liver disease. J Magn Reson Imaging 39 (2014), 1525–1532.
18. [18] El-Hassan, A.Y., Ibrahim, E.M., Al-Mulhim, F.A., et al. Fatty infiltration of the liver: analysis of prevalence, radiological and clinical features and influence on patient management. Br J Radiol 65 (1992), 774–778.
19. [19] Grove, A., Vyberg, B., Vyberg, M., Focal fatty change of the liver. A review and a case associated with continuous ambulatory peritoneal dialysis. Virchows Arch 419 (1991), 69–75.
20. [20] Merriman, R.B., Ferrell, L.D., Patti, M.G., et al. Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease. Hepatology 44 (2006), 874–880.
21. [21] Larson, S.P., Bowers, S.P., Palekar, N.A., et al. Histopathologic variability between the right and left lobes of the liver in morbidly obese patients undergoing Roux-en-Y bypass. Clin Gastroenterol Hepatol 5 (2007), 1329–1332.
22. [22] Ratziu, V., Charlotte, F., Heurtier, A., et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 128 (2005), 1898–1906.
23. [23] Lee, S.S., Park, S.H., Radiologic evaluation of nonalcoholic fatty liver disease. World J Gastroenterol 20 (2014), 7392–7402.
24. [24] Papagianni, M., Sofogianni, A., Tziomalos, K., Non-invasive methods for the diagnosis of nonalcoholic fatty liver disease. World J Hepatol 7 (2015), 638–648.
25. [25] Cui, J., Ang, B., Haufe, W., et al. Comparative diagnostic accuracy of magnetic resonance elastography vs. eight clinical prediction rules for non-invasive diagnosis of advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease: a prospective study. Aliment Pharmacol Ther 41 (2015), 1271–1280.
26. [26] Singh, S., Venkatesh, S.K., Wang, Z., et al. Diagnostic performance of magnetic resonance elastography in staging liver fibrosis: a systematic review and meta-analysis of individual participant data. Clin Gastroenterol Hepatol 13 (2015), 440–451, e6.
27. [27] Idilman, I.S., Keskin, O., Celik, A., et al. A comparison of liver fat content as determined by magnetic resonance imaging-proton density fat fraction and MRS vs. liver histology in non-alcoholic fatty liver disease. Acta Radiol 57 (2016), 271–278.
28. [28] Tang, A., Desai, A., Hamilton, G., et al. Accuracy of MR imaging-estimated proton density fat fraction for classification of dichotomized histologic steatosis grades in nonalcoholic fatty liver disease. Radiology 274 (2015), 416–425.
29. [29] Permutt, Z., Le, T.A., Peterson, M.R., et al. Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease - MRI accurately quantifies hepatic steatosis in NAFLD. Aliment Pharmacol Ther 36 (2012), 22–29.
30. [30] Loomba, R., Wolfson, T., Ang, B., et al. Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective study. Hepatology 60 (2014), 1920–1928.
31. [31] NIH Definitions Working Group, Biomarkers and surrogate endpoints in clinical research: definitions and conceptual model. Downing, G.J., (eds.) Biomarkers and Surrogate Endpoints, 2000, Elsevier, Amsterdam, 1–9.
32. [32] Aronson, J.K., Biomarkers and surrogate endpoints. Br J Clin Pharmacol 59 (2005), 491–494.
33. [33] Aronson, J.K., Research priorities in biomarkers and surrogate end-points. Br J Clin Pharmacol 73 (2012), 900–907.
34. [34] Aronson, J.K., Surrogate end points: studying their benefits, taxonomy, and semantics. BMJ, 344, 2012, e750.
35. [35] Fleming, T.R., Surrogate endpoints and FDA's accelerated approval process. Health Aff (Millwood) 24 (2005), 67–78.
36. [36] FDA Document. Guidance for Industry Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs and Biological Products December, 2012.
37. [37] Kirshner, B., Guyatt, G., A methodological framework for assessing health indices. J Chronic Dis 38 (1985), 27–36.
38. [38] Wagner, J.A., Overview of biomarkers and surrogate endpoints in drug development. Dis Markers 18 (2002), 41–46.
39. [39] Lee, J.W., Devanarayan, V., Barrett, Y.C., et al. Fit-for-purpose method development and validation for successful biomarker measurement. Pharm Res 23 (2006), 312–328.
40. [40] Fleming, T.R., DeMets, D.L., Surrogate end points in clinical trials: are we being misled?. Ann Intern Med 125 (1996), 605–613.
41. [41] Prentice, R.L., Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 8 (1989), 431–440.
42. [42] Yokoo, T., Bydder, M., Hamilton, G., et al. Nonalcoholic fatty liver disease: diagnostic and fat-grading accuracy of low-flip-angle multiecho gradient-recalled-echo MR imaging at 1.5 T. Radiology 251 (2009), 67–76.
43. [43] Yokoo, T., Shiehmorteza, M., Hamilton, G., et al. Estimation of hepatic proton-density fat fraction by using MR imaging at 3.0 T. Radiology 258 (2011), 749–759.
44. [44] Lee, S.S., Lee, Y., Kim, N., et al. Hepatic fat quantification using chemical shift MR imaging and MR spectroscopy in the presence of hepatic iron deposition: validation in phantoms and in patients with chronic liver disease. J Magn Reson Imaging 33 (2011), 1390–1398.
45. [45] Guiu, B., Petit, J.M., Loffroy, R., et al. Quantification of liver fat content: comparison of triple-echo chemical shift gradient-echo imaging and in vivo proton MR spectroscopy. Radiology 250 (2009), 95–102.
46. [46] Bydder, M., Shiehmorteza, M., Yokoo, T., et al. Assessment of liver fat quantification in the presence of iron. Magn Reson Imaging 28 (2010), 767–776.
47. [47] Kang, B.K., Yu, E.S., Lee, S.S., et al. Hepatic fat quantification: a prospective comparison of magnetic resonance spectroscopy and analysis methods for chemical-shift gradient echo magnetic resonance imaging with histologic assessment as the reference standard. Invest Radiol 47 (2012), 368–375.
48. [48] Kuhn, J.P., Hernando, D., Munoz del Rio, A., et al. Effect of multipeak spectral modeling of fat for liver iron and fat quantification: correlation of biopsy with MR imaging results. Radiology 265 (2012), 133–142.
49. [49] Meisamy, S., Hines, C.D., Hamilton, G., et al. Quantification of hepatic steatosis with T1-independent, T2-corrected MR imaging with spectral modeling of fat: blinded comparison with MR spectroscopy. Radiology 258 (2011), 767–775.
50. [50] Hines, C.D., Yu, H., Shimakawa, A., et al. T1 independent, T2∗ corrected MRI with accurate spectral modeling for quantification of fat: validation in a fat-water-SPIO phantom. J Magn Reson Imaging 30 (2009), 1215–1222.
51. [51] Reeder, S.B., Robson, P.M., Yu, H., et al. Quantification of hepatic steatosis with MRI: the effects of accurate fat spectral modeling. J Magn Reson Imaging 29 (2009), 1332–1339.
52. [52] Yu, H., Shimakawa, A., McKenzie, C.A., et al. Multiecho water-fat separation and simultaneous R2∗ estimation with multifrequency fat spectrum modeling. Magn Reson Med 60 (2008), 1122–1134.
53. [53] Tang, A., Tan, J., Sun, M., et al. Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis. Radiology 267 (2013), 422–431.
54. [54] Kang, G.H., Cruite, I., Shiehmorteza, M., et al. Reproducibility of MRI-determined proton density fat fraction across two different MR scanner platforms. J Magn Reson Imaging 34 (2011), 928–934.
55. [55] Kleiner, D.E., Brunt, E.M., Van Natta, M., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41 (2005), 1313–1321.
56. [56] Idilman, I.S., Aniktar, H., Idilman, R., et al. Hepatic steatosis: quantification by proton density fat fraction with MR imaging vs. liver biopsy. Radiology 267 (2013), 767–775.
57. [57] Bannas, P., Kramer, H., Hernando, D., et al. Quantitative magnetic resonance imaging of hepatic steatosis: Validation in ex vivo human livers. Hepatology 62 (2015), 1444–1455.
58. [58] Heba, E.R., Desai, A., Zand, K.A., et al. Accuracy and the effect of possible subject-based confounders of magnitude-based MRI for estimating hepatic proton density fat fraction in adults, using MR spectroscopy as reference. J Magn Reson Imaging 43 (2016), 398–406.
59. [59] Paparo, F., Cenderello, G., Revelli, M., et al. Diagnostic value of MRI proton density fat fraction for assessing liver steatosis in chronic viral C hepatitis. Biomed Res Int, 2015, 2015, 758164.
60. [60] Negrete, L.M., Middleton, M.S., Clark, L., et al. Inter-examination precision of magnitude-based MRI for estimation of segmental hepatic proton density fat fraction in obese subjects. J Magn Reson Imaging 39 (2014), 1265–1271.
61. [61] Tyagi, A., Yeganeh, O., Levin, Y., et al. Intra- and inter-examination repeatability of magnetic resonance spectroscopy, magnitude-based MRI, and complex-based MRI for estimation of hepatic proton density fat fraction in overweight and obese children and adults. Abdom Imaging 40 (2015), 3070–3077.
62. [62] Le, T.A., Chen, J., Changchien, C., et al. Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial. Hepatology 56 (2012), 922–932.
63. [63] Noureddin, M., Lam, J., Peterson, M.R., et al. Utility of magnetic resonance imaging vs. histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. Hepatology 58 (2013), 1930–1940.
64. [64] Hamilton, G., Middleton, M.S., Bydder, M., et al. Effect of PRESS and STEAM sequences on magnetic resonance spectroscopic liver fat quantification. J Magn Reson Imaging 30 (2009), 145–152.
65. [65] Cassidy, F.H., Yokoo, T., Aganovic, L., et al. Fatty liver disease: MR imaging techniques for the detection and quantification of liver steatosis. Radiographics 29 (2009), 231–260.
66. [66] Khov, N., Sharma, A., Riley, T.R., Bedside ultrasound in the diagnosis of nonalcoholic fatty liver disease. World J Gastroenterol 20 (2014), 6821–6825.
67. [67] Dasarathy, S., Dasarathy, J., Khiyami, A., et al. Validity of real time ultrasound in the diagnosis of hepatic steatosis: a prospective study. J Hepatol 51 (2009), 1061–1067.
68. [68] Hamaguchi, M., Kojima, T., Itoh, Y., et al. The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol 102 (2007), 2708–2715.
69. [69] Riley, T.R., Bruno, M.A., Sonographic measurement of the thickness of subcutaneous tissues in nonalcoholic fatty liver disease vs. other chronic liver diseases. J Clin Ultrasound 33 (2005), 439–441.
70. [70] Riley, T.R. 3rd, Mendoza, A., Bruno, M.A., Bedside ultrasound can predict nonalcoholic fatty liver disease in the hands of clinicians using a prototype image. Dig Dis Sci 51 (2006), 982–985.
71. [71] Riley, T.R. 3rd, Kahn, A., Risk factors and ultrasound can predict chronic hepatitis caused by nonalcoholic fatty liver disease. Dig Dis Sci 51 (2006), 41–44.
72. [72] Lee, J.Y., Kim, K.M., Lee, S.G., et al. Prevalence and risk factors of non-alcoholic fatty liver disease in potential living liver donors in Korea: a review of 589 consecutive liver biopsies in a single center. J Hepatol 47 (2007), 239–244.
73. [73] Lee, S.S., Park, S.H., Kim, H.J., et al. Non-invasive assessment of hepatic steatosis: prospective comparison of the accuracy of imaging examinations. J Hepatol 52 (2010), 579–585.
74. [74] Williams, C.D., Stengel, J., Asike, M.I., et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 140 (2011), 124–131.
75. [75] Mishra, P., Younossi, Z.M., Abdominal ultrasound for diagnosis of nonalcoholic fatty liver disease (NAFLD). Am J Gastroenterol 102 (2007), 2716–2717.
76. [76] Guajardo-Salinas, G.E., Hilmy, A., Prevalence of nonalcoholic fatty liver disease (NAFLD) and utility of FIBROspect II to detect liver fibrosis in morbidly obese Hispano-American patients undergoing gastric bypass. Obes Surg 20 (2010), 1647–1653.
77. [77] de Moura, Almeida A., Cotrim, H.P., Barbosa, D.B., et al. Fatty liver disease in severe obese patients: diagnostic value of abdominal ultrasound. World J Gastroenterol 14 (2008), 1415–1418.
78. [78] Perez, N.E., Siddiqui, F.A., Mutchnick, M.G., et al. Ultrasound diagnosis of fatty liver in patients with chronic liver disease: a retrospective observational study. J Clin Gastroenterol 41 (2007), 624–629.
79. [79] Chen, C.H., Lin, S.T., Yang, C.C., et al. The accuracy of sonography in predicting steatosis and fibrosis in chronic hepatitis C. Dig Dis Sci 53 (2008), 1699–1706.
80. [80] Lin, S.C., Heba, E., Wolfson, T., et al. Noninvasive diagnosis of nonalcoholic fatty liver disease and quantification of liver fat using a new quantitative ultrasound technique. Clin Gastroenterol Hepatol 13 (2015), 1337–1345, e6.
81. [81] Sasso, M., Audiere, S., Kemgang, A., et al. Liver steatosis assessed by controlled attenuation parameter (CAP) measured with the XL probe of the FibroScan: a pilot study assessing diagnostic accuracy. Ultrasound Med Biol 42 (2016), 92–103.
82. [82] Sasso, M., Beaugrand, M., de Ledinghen, V., et al. Controlled attenuation parameter (CAP): a novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol 36 (2010), 1825–1835.
83. [83] de Ledinghen, V., Vergniol, J., Foucher, J., et al. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography. Liver Int 32 (2012), 911–918.
84. [84] Myers, R.P., Pollett, A., Kirsch, R., et al. Controlled attenuation parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography. Liver Int 32 (2012), 902–910.
85. [85] Chon, Y.E., Jung, K.S., Kim, S.U., et al. Controlled attenuation parameter (CAP) for detection of hepatic steatosis in patients with chronic liver diseases: a prospective study of a native Korean population. Liver Int 34 (2014), 102–109.
86. [86] Chan, W.K., Nik Mustapha, N.R., Mahadeva, S., Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease. J Gastroenterol Hepatol 29 (2014), 1470–1476.
87. [87] Shen, F., Zheng, R.D., Mi, Y.Q., et al. Controlled attenuation parameter for non-invasive assessment of hepatic steatosis in Chinese patients. World J Gastroenterol 20 (2014), 4702–4711.
88. [88] Imajo, K., Kessoku, T., Honda, Y., et al. Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography. Gastroenterology 150 (2016), 626–637, e7.
89. [89] Schwimmer, J.B., Middleton, M.S., Behling, C., et al. Magnetic resonance imaging and liver histology as biomarkers of hepatic steatosis in children with nonalcoholic fatty liver disease. Hepatology 61 (2015), 1887–1895.
90. [90] Venkatesh, S.K., Yin, M., Ehman, R.L., Magnetic resonance elastography of liver: technique, analysis, and clinical applications. J Magn Reson Imaging 37 (2013), 544–555.
91. [91] Kim, D., Kim, W.R., Talwalkar, J.A., et al. Advanced fibrosis in nonalcoholic fatty liver disease: noninvasive assessment with MR elastography. Radiology 268 (2013), 411–419.
92. [92] Singh, S., Venkatesh, S.K., Loomba, R., et al. Magnetic resonance elastography for staging liver fibrosis in non-alcoholic fatty liver disease: a diagnostic accuracy systematic review and individual participant data pooled analysis. Eur Radiol 26 (2016), 1431–1440.
93. [93] Chen, J., Talwalkar, J.A., Yin, M., et al. Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography. Radiology 259 (2011), 749–756.
94. [94] Loomba, R., Cui, J., Wolfson, T., et al. Novel 3D magnetic resonance elastography for the noninvasive diagnosis of advanced fibrosis in NAFLD: a prospective study. Am J Gastroenterol 111 (2016), 986–994.
95. [95] Runge, J.H., Bohte, A.E., Verheij, J., et al. Comparison of interobserver agreement of magnetic resonance elastography with histopathological staging of liver fibrosis. Abdom Imaging 39 (2014), 283–290.
96. [96] Tiniakos, D.G., Nonalcoholic fatty liver disease/nonalcoholic steatohepatitis: histological diagnostic criteria and scoring systems. Eur J Gastroenterol Hepatol 22 (2010), 643–650.
97. [97] Harrison, S.A., Torgerson, S., Hayashi, P.H., The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am J Gastroenterol 98 (2003), 2042–2047.
98. [98] Powell, E.E., Cooksley, W.G., Hanson, R., et al. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 11 (1990), 74–80.
99. [99] Fassio, E., Alvarez, E., Dominguez, N., et al. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology 40 (2004), 820–826.
100. [100] Evans, C.D., Oien, K.A., MacSween, R.N., et al. Non-alcoholic steatohepatitis: a common cause of progressive chronic liver injury?. J Clin Pathol 55 (2002), 689–692.
101. [101] Gaidos, J.K., Hillner, B.E., Sanyal, A.J., A decision analysis study of the value of a liver biopsy in nonalcoholic steatohepatitis. Liver Int 28 (2008), 650–658.
102. [102] Shiina, T., Nightingale, K.R., Palmeri, M.L., et al. WFUMB guidelines and recommendations for clinical use of ultrasound elastography: Part 1: basic principles and terminology. Ultrasound Med Biol 41 (2015), 1126–1147.
103. [103] Ferraioli, G., Filice, C., Castera, L., et al. WFUMB guidelines and recommendations for clinical use of ultrasound elastography: Part 3: liver. Ultrasound Med Biol 41 (2015), 1161–1179.
104. [104] Tsochatzis, E.A., Gurusamy, K.S., Ntaoula, S., et al. Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy. J Hepatol 54 (2011), 650–659.
105. [105] Tsochatzis, E.A., Manousou, P., Fede, G., et al. Validating non-invasive markers of fibrosis: the need for a new histological reference standard. Gut 60 (2011), 1442–1443 [Author reply 1443–4].
106. [106] Nierhoff, J., Chavez Ortiz, A.A., Herrmann, E., et al. The efficiency of acoustic radiation force impulse imaging for the staging of liver fibrosis: a meta-analysis. Eur Radiol 23 (2013), 3040–3053.
107. [107] Cui, J., Philo, L., Nguyen, P., et al. Sitagliptin vs. placebo in the treatment of nonalcoholic fatty liver disease: A randomized controlled trial. J Hepatol 65 (2016), 369–376.
108. [108] Yoon, J.H., Lee, J.M., Woo, H.S., et al. Staging of hepatic fibrosis: comparison of magnetic resonance elastography and shear wave elastography in the same individuals. Korean J Radiol 14 (2013), 202–212.
109. [109] Huwart, L., Sempoux, C., Vicaut, E., et al. Magnetic resonance elastography for the noninvasive staging of liver fibrosis. Gastroenterology 135 (2008), 32–40.
110. [110] Yoon, J.H., Lee, J.M., Joo, I., et al. Hepatic fibrosis: prospective comparison of MR elastography and US shear-wave elastography for evaluation. Radiology 273 (2014), 772–782.
111. [111] Castera, L., Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology 142 (2012), 1293–1302, e4.
112. [112] Castera, L., Foucher, J., Bernard, P.H., et al. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology 51 (2010), 828–835.
113. [113] Bota, S., Sporea, I., Sirli, R., et al. Factors associated with the impossibility to obtain reliable liver stiffness measurements by means of Acoustic Radiation Force Impulse (ARFI) elastography–analysis of a cohort of 1,031 subjects. Eur J Radiol 83 (2014), 268–272.
114. [114] Castera, L., Pinzani, M., Non-invasive assessment of liver fibrosis: are we ready?. Lancet 375 (2010), 1419–1420.
115. [115] Talwalkar, J.A., Elastography for detecting hepatic fibrosis: options and considerations. Gastroenterology 135 (2008), 299–302.
116. [116] Wong, V.W., Vergniol, J., Wong, G.L., et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 51 (2010), 454–462.
117. [117] Gradinaru-Tascau, O., Sporea, I., Bota, S., et al. Does experience play a role in the ability to perform liver stiffness measurements by means of supersonic shear imaging (SSI)?. Med Ultrason 15 (2013), 180–183.
118. [118] EASL-ALEH clinical practice guidelines: non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol 63 (2015), 237–264.
119. [119] Loomba, R., Sirlin, C.B., Ang, B., et al. Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial). Hepatology 61 (2015), 1239–1250.
120. [120] Doycheva, I., Cui, J., Nguyen, P., et al. Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE. Aliment Pharmacol Ther 43 (2016), 83–95.
121. [121] Kwok, R., Choi, K.C., Wong, G.L., et al. Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study. Gut 65 (2016), 1359–1368.
122. [122] Banerjee, R., Pavlides, M., Tunnicliffe, E.M., et al. Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease. J Hepatol 60 (2014), 69–77.